Clinical advances in hematology & oncology : H&O

Keyphrases

Publications

number 6, 2024

Alexander Drilon
Management of patients with NTRK fusion-positive lung cancer. Clinical advances in hematology & oncology : H&O (6) (2024)
David S Hong
Diagnosing NTRK fusions in lung and thyroid cancer. Clinical advances in hematology & oncology : H&O (6) (2024)
David S Hong, Alexander Drilon, Lori J Wirth
Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers. Clinical advances in hematology & oncology : H&O (6) (2024)
Lori J Wirth
Management of patients with NTRK fusion-positive thyroid cancer. Clinical advances in hematology & oncology : H&O (6) (2024)
Lori J Wirth
Management of patients with NTRK fusion-positive thyroid cancer. Clinical advances in hematology & oncology : H&O (6) (2024)
David S Hong, Alexander Drilon, Lori J Wirth
Q&A: Barriers to testing for NTRK fusions in metastatic lung and thyroid cancer. Clinical advances in hematology & oncology : H&O (6) (2024)
David S Hong
Diagnosing NTRK fusions in lung and thyroid cancer. Clinical advances in hematology & oncology : H&O (6) (2024)
David S Hong, Alexander Drilon, Lori J Wirth
Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers. Clinical advances in hematology & oncology : H&O (6) (2024)

volume 22, number 1, 2024

Peter Li, Christian Agbisit, Marcus Noel, Reetu Mukherji
Evolving applications of liquid biopsies in gastrointestinal cancers. Clinical advances in hematology & oncology : H&O 22 (1) (2024)
Ramez N Eskander
Revisiting immunotherapy in endometrial cancer. Clinical advances in hematology & oncology : H&O 22 (1) (2024)
Virginia Kaklamani
Sequencing therapies: optimal treatment for HR+/HER2- metastatic breast cancer. Clinical advances in hematology & oncology : H&O 22 (1) (2024)
Julian A Waksal, Nicole E Wagner, John O Mascarenhas
Risk factors for disease progression and treatment goals in polycythemia vera. Clinical advances in hematology & oncology : H&O 22 (1) (2024)
Rahul Aggarwal
Biomarkers and novel PET imaging to detect neuroendocrine prostate cancer. Clinical advances in hematology & oncology : H&O 22 (1) (2024)
Ramez N Eskander
Revisiting immunotherapy in endometrial cancer. Clinical advances in hematology & oncology : H&O 22 (1) (2024)
Lorenzo Falchi
The use of glofitamab in relapsed diffuse large B-cell lymphoma. Clinical advances in hematology & oncology : H&O 22 (1) (2024)
Lorenzo Falchi
The use of glofitamab in relapsed diffuse large B-cell lymphoma. Clinical advances in hematology & oncology : H&O 22 (1) (2024)
Adrian Wiestner
Genomic risk stratification in chronic lymphocytic leukemia. Clinical advances in hematology & oncology : H&O 22 (1) (2024)

volume 22, number 2, 2024

Jyoti Malhotra, Danny Nguyen, Tingting Tan, George B Semeniuk Iii
Management of KRAS -mutated non-small cell lung cancer. Clinical advances in hematology & oncology : H&O 22 (2) (2024)
Sandy El Bitar, Murat O Arcasoy
Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms. Clinical advances in hematology & oncology : H&O 22 (2) (2024)
Arnon Kater
Epcoritamab, a promising therapy for Richter syndrome? Clinical advances in hematology & oncology : H&O 22 (2) (2024)

volume 22, number 3, 2024

Juan Francisco Grau-Bejar, Lorena Farinas-Madrid, Carmen García-Duran, David García-Illescas, Roberta Mazzeo, Ana Oaknin
Immunotherapy in the treatment of advanced or recurrent endometrial cancer. Clinical advances in hematology & oncology : H&O 22 (3) (2024)
Patricia K Nguyen
Thrombotic complications of influenza and COVID-19 infections. Clinical advances in hematology & oncology : H&O 22 (3) (2024)
Fateeha Furqan, Nirav N Shah
The role of noncovalent BTK inhibitors in the era of covalent BTK inhibitors. Clinical advances in hematology & oncology : H&O 22 (3) (2024)
Kathi Vidal
Coordination between the FDA and the US Patent and Trademark Office. Clinical advances in hematology & oncology : H&O 22 (3) (2024)
Jeff Sharman
Six-year update of the ELEVATE-TN study on acalabrutinib. Clinical advances in hematology & oncology : H&O 22 (3) (2024)

volume 22, number 4, 2024

Bashar A Aqel
Liver transplant in patients with metastatic colorectal cancer. Clinical advances in hematology & oncology : H&O 22 (4) (2024)
Ghayas C Issa
The development of menin inhibitors in AML and ALL. Clinical advances in hematology & oncology : H&O 22 (4) (2024)
Peter A Fasching
PROTAC drugs in cancer care. Clinical advances in hematology & oncology : H&O 22 (4) (2024)
Emily C Harrold, Fergus Keane, Andrea Cercek
Immune checkpoint inhibitor therapy in locally advanced MSI GI malignancies. Clinical advances in hematology & oncology : H&O 22 (4) (2024)
Emily C Harrold, Fergus Keane, Andrea Cercek
Immune checkpoint inhibitor therapy in locally advanced MSI GI malignancies. Clinical advances in hematology & oncology : H&O 22 (4) (2024)
Ammanuel Taye, Ahmed Elkhanany, Erica Stringer-Reasor
Increasing inclusion and equity for Black women in breast cancer clinical trials. Clinical advances in hematology & oncology : H&O 22 (4) (2024)
Ammanuel Taye, Ahmed Elkhanany, Erica Stringer-Reasor
Increasing inclusion and equity for Black women in breast cancer clinical trials. Clinical advances in hematology & oncology : H&O 22 (4) (2024)

volume 22, number 5, 2024

Joshua E Reuss, Samuel Rosner, Benjamin P Levy
Antibody-drug conjugates in advanced lung cancer: Is this a new frontier? Clinical advances in hematology & oncology : H&O 22 (5) (2024)
Beryl L Manning-Geist, Tal Cantor, Róisín E O'Cearbhaill, Rachel N Grisham
Redefining the standard of care for low-grade serous ovarian cancer. Clinical advances in hematology & oncology : H&O 22 (5) (2024)
Wm Kevin Kelly
STEAP1 as a potential target for new therapies in prostate cancer. Clinical advances in hematology & oncology : H&O 22 (5) (2024)
Ian F Tannock
New drug approvals for prostate cancer. Clinical advances in hematology & oncology : H&O 22 (5) (2024)
Wm Kevin Kelly
STEAP1 as a potential target for new therapies in prostate cancer. Clinical advances in hematology & oncology : H&O 22 (5) (2024)
Vernon K Sondak
The evolving role of surgery in melanoma. Clinical advances in hematology & oncology : H&O 22 (5) (2024)
Joshua E Reuss, Samuel Rosner, Benjamin P Levy
Antibody-drug conjugates in advanced lung cancer: Is this a new frontier? Clinical advances in hematology & oncology : H&O 22 (5) (2024)
Jennifer A Woyach
Pirtobrutinib in relapsed or refractory CLL and SLL. Clinical advances in hematology & oncology : H&O 22 (5) (2024)
Beryl L Manning-Geist, Tal Cantor, Róisín E O'Cearbhaill, Rachel N Grisham
Redefining the standard of care for low-grade serous ovarian cancer. Clinical advances in hematology & oncology : H&O 22 (5) (2024)

volume 22, number 6, 2024

Caron A Jacobson
Pilot data on axicabtagene ciloleucel for CNS lymphoma. Clinical advances in hematology & oncology : H&O 22 (6) (2024)
Jamie E Chaft
Can unresectable non-small cell lung cancer become resectable? Clinical advances in hematology & oncology : H&O 22 (6) (2024)
Elizabeth K Lee, Joyce F Liu
Uterine serous carcinoma and uterine carcinosarcoma: molecular features, clinical advances, and emerging therapies. Clinical advances in hematology & oncology : H&O 22 (6) (2024)
William G Wierda
The approval of lisocabtagene maraleucel in chronic lymphocytic leukemia. Clinical advances in hematology & oncology : H&O 22 (6) (2024)
Sara M Tolaney
Update on CDK4/6 inhibitors in breast cancer. Clinical advances in hematology & oncology : H&O 22 (6) (2024)

volume 22, number 7, 2024

Randy F Sweis
STING activators in cancer care. Clinical advances in hematology & oncology : H&O 22 (7) (2024)
Robin Foà
Can we cure Ph+ ALL without chemotherapy or transplant? Clinical advances in hematology & oncology : H&O 22 (7) (2024)
Jyoti Malhotra
HER2-targeted therapies in non-small cell lung cancer. Clinical advances in hematology & oncology : H&O 22 (7) (2024)
Kelly S Chien, Courtney D DiNardo, Guillermo Garcia-Manero
Clonal hematopoiesis: malignant implications, extrahematologic manifestations, and management. Clinical advances in hematology & oncology : H&O 22 (7) (2024)